[{"id":"adavosertib","name":"Adavosertib","tldr":"Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.","route":"/drugs/adavosertib/","status":"phase-2","kind":"drug","molecule":"adavosertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"alisertib","name":"Alisertib","tldr":"Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.","route":"/drugs/alisertib/","status":"phase-2","kind":"drug","molecule":"alisertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"amo959","name":"AMO959","tldr":"AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.","route":"/drugs/amo959/","status":"phase-2","kind":"drug","molecule":"amo959","modality":"Small-molecule inhibitor","sub":"AMO959","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"amt-116","name":"AMT-116","tldr":"AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/amt-116/","status":"phase-2","kind":"drug","molecule":"amt-116","modality":"Antibody-drug conjugate","sub":"AMT-116","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"ard103","name":"ARD103","tldr":"ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.","route":"/drugs/ard103/","status":"phase-2","kind":"drug","molecule":"ard103","modality":"CAR-T cell therapy","sub":"ARD103","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"au-007","name":"AU-007","tldr":"AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.","route":"/drugs/au-007/","status":"phase-2","kind":"drug","molecule":"au-007","modality":"Monoclonal antibody","sub":"AU-007","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","Melanoma","Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"avzo-023","name":"AVZO-023","tldr":"AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/avzo-023/","status":"phase-2","kind":"drug","molecule":"avzo-023","modality":"Small-molecule inhibitor","sub":"AVZO-023","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"azd0120","name":"AZD0120","tldr":"AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.","route":"/drugs/azd0120/","status":"phase-3","kind":"drug","molecule":"azd0120","modality":"CAR-T cell therapy","sub":"AZD0120","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"azd8421","name":"AZD8421","tldr":"AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.","route":"/drugs/azd8421/","status":"phase-2","kind":"drug","molecule":"azd8421","modality":"Small-molecule inhibitor","sub":"AZD8421","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"balstilimab","name":"Balstilimab","tldr":"Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.","route":"/drugs/balstilimab/","status":"phase-2","kind":"drug","molecule":"balstilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"befotertinib","name":"Befotertinib","tldr":"Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/befotertinib/","status":"phase-2","kind":"drug","molecule":"befotertinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"beijing-gene-key-life-technology","name":"Beijing Gene Key Life Technology","tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.","route":"/companies/beijing-gene-key-life-technology/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"beijing-konruns-pharmaceutical","name":"Beijing Konruns Pharmaceutical","tldr":"Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.","route":"/companies/beijing-konruns-pharmaceutical/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=konruns.cn&sz=128","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"beijing-mabworks-biotech","name":"Beijing Mabworks Biotech","tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.","route":"/companies/beijing-mabworks-biotech/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"beijing-pearl-biotechnology-limited-liability-company","name":"Beijing Pearl Biotechnology Limited Liability Company","tldr":"Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"beijing-scitech-mq-pharmaceuticals","name":"Beijing Scitech-Mq Pharmaceuticals","tldr":"Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898.","route":"/companies/beijing-scitech-mq-pharmaceuticals/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"beijing-tide-pharmaceutical","name":"Beijing Tide Pharmaceutical","tldr":"Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727.","route":"/companies/beijing-tide-pharmaceutical/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=tidepharm.com&sz=128","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"bexmarilimab","name":"Bexmarilimab","tldr":"Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms.","route":"/drugs/bexmarilimab/","status":"phase-2","kind":"drug","molecule":"bexmarilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"binhui-biopharmaceutical","name":"Binhui Biopharmaceutical","tldr":"Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008.","route":"/companies/binhui-biopharmaceutical/","kind":"company","avatar":"org","sub":"Wuhan, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"boserolimab","name":"Boserolimab","tldr":"Boserolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/boserolimab/","status":"phase-2","kind":"drug","molecule":"boserolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"camonsertib","name":"Camonsertib","tldr":"Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.","route":"/drugs/camonsertib/","status":"phase-2","kind":"drug","molecule":"camonsertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"chengdu-zenitar-biomedical-technology","name":"Chengdu Zenitar Biomedical Technology","tldr":"Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.","route":"/companies/chengdu-zenitar-biomedical-technology/","kind":"company","avatar":"org","sub":"Chengdu, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"ct3001","name":"CT3001","tldr":"CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/ct3001/","status":"phase-2","kind":"drug","molecule":"ct3001","modality":"Small-molecule inhibitor","sub":"CT3001","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"cyh33","name":"CYH33","tldr":"CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.","route":"/drugs/cyh33/","status":"phase-2","kind":"drug","molecule":"cyh33","modality":"Small-molecule inhibitor","sub":"CYH33","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"doc1021","name":"DOC1021","tldr":"DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.","route":"/drugs/doc1021/","status":"phase-2","kind":"drug","molecule":"doc1021","modality":"Cancer vaccine","sub":"DOC1021","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"dr-01","name":"DR-01","tldr":"DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas.","route":"/drugs/dr-01/","status":"phase-2","kind":"drug","molecule":"dr-01","modality":"Monoclonal antibody","sub":"DR-01","facets":{"kind":["Treatment"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"eik1005","name":"EIK1005","tldr":"EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.","route":"/drugs/eik1005/","status":"phase-2","kind":"drug","molecule":"eik1005","modality":"Small-molecule inhibitor","sub":"EIK1005","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"emavusertib","name":"Emavusertib","tldr":"Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.","route":"/drugs/emavusertib/","status":"phase-2","kind":"drug","molecule":"emavusertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Chronic lymphocytic leukaemia","Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"enb003","name":"ENB003","tldr":"ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.","route":"/drugs/enb003/","status":"phase-2","kind":"drug","molecule":"enb003","modality":"Small-molecule antagonist","sub":"ENB003","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"evexomostat","name":"Evexomostat","tldr":"Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/evexomostat/","status":"phase-2","kind":"drug","molecule":"evexomostat","modality":"Small-molecule inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"evm14","name":"EVM14","tldr":"EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/evm14/","status":"phase-2","kind":"drug","molecule":"evm14","modality":"Cancer vaccine","sub":"EVM14","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"farletuzumab-ecteribulin","name":"Farletuzumab ecteribulin","tldr":"Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/farletuzumab-ecteribulin/","status":"phase-2","kind":"drug","molecule":"farletuzumab-ecteribulin","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"feladilimab","name":"Feladilimab","tldr":"Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma.","route":"/drugs/feladilimab/","status":"phase-2","kind":"drug","molecule":"feladilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"flonoltinib","name":"Flonoltinib","tldr":"Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.","route":"/drugs/flonoltinib/","status":"phase-2","kind":"drug","molecule":"flonoltinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"fluzoparib","name":"Fluzoparib","tldr":"Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/fluzoparib/","status":"phase-2","kind":"drug","molecule":"fluzoparib","modality":"Oral PARP inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"gecacitinib","name":"Gecacitinib","tldr":"Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.","route":"/drugs/gecacitinib/","status":"phase-2","kind":"drug","molecule":"gecacitinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"henan-genuine-biotech","name":"Henan Genuine Biotech","tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib.","route":"/companies/henan-genuine-biotech/","kind":"company","logo":"/logos/henan-genuine-biotech.png","avatar":"org","sub":"Henan, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"hst-1011","name":"HST-1011","tldr":"HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/hst-1011/","status":"phase-2","kind":"drug","molecule":"hst-1011","modality":"Small-molecule inhibitor","sub":"HST-1011","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"immvira-pharma","name":"ImmVira Pharma","tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.","route":"/companies/immvira-pharma/","kind":"company","avatar":"org","sub":"Shenzhen, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"imp1734","name":"IMP1734","tldr":"IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.","route":"/drugs/imp1734/","status":"phase-2","kind":"drug","molecule":"imp1734","modality":"Small-molecule inhibitor","sub":"IMP1734","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"inlexisertib","name":"Inlexisertib","tldr":"Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer.","route":"/drugs/inlexisertib/","status":"phase-2","kind":"drug","molecule":"inlexisertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"ipg1094","name":"IPG1094","tldr":"IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/ipg1094/","status":"phase-2","kind":"drug","molecule":"ipg1094","modality":"Small-molecule inhibitor","sub":"IPG1094","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"jacobio-pharmaceuticals","name":"Jacobio Pharmaceuticals","tldr":"Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.","route":"/companies/jacobio-pharmaceuticals/","kind":"company","logo":"/logos/jacobio-pharmaceuticals.png","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"jbi-802","name":"JBI-802","tldr":"JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.","route":"/drugs/jbi-802/","status":"phase-2","kind":"drug","molecule":"jbi-802","modality":"Small-molecule inhibitor","sub":"JBI-802","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"jmt203","name":"JMT203","tldr":"JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer.","route":"/drugs/jmt203/","status":"phase-2","kind":"drug","molecule":"jmt203","modality":"Monoclonal antibody","sub":"JMT203","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"lp-184","name":"LP-184","tldr":"LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/lp-184/","status":"phase-2","kind":"drug","molecule":"lp-184","modality":"Small-molecule inhibitor","sub":"LP-184","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"lvgn6051","name":"LVGN6051","tldr":"LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.","route":"/drugs/lvgn6051/","status":"phase-2","kind":"drug","molecule":"lvgn6051","modality":"Monoclonal antibody","sub":"LVGN6051","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"merestinib","name":"Merestinib","tldr":"Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer.","route":"/drugs/merestinib/","status":"phase-2","kind":"drug","molecule":"merestinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"mhb036c","name":"MHB036C","tldr":"MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/mhb036c/","status":"phase-2","kind":"drug","molecule":"mhb036c","modality":"Antibody-drug conjugate","sub":"MHB036C","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"mhb039a","name":"MHB039A","tldr":"MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/mhb039a/","status":"phase-2","kind":"drug","molecule":"mhb039a","modality":"Bispecific antibody","sub":"MHB039A","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"mitazalimab","name":"Mitazalimab","tldr":"Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/mitazalimab/","status":"phase-2","kind":"drug","molecule":"mitazalimab","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"nanjing-immunophage-biotech","name":"Nanjing Immunophage Biotech","tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.","route":"/companies/nanjing-immunophage-biotech/","kind":"company","avatar":"org","sub":"Nanjing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"np137","name":"NP137","tldr":"NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer.","route":"/drugs/np137/","status":"phase-2","kind":"drug","molecule":"np137","modality":"Monoclonal antibody","sub":"NP137","facets":{"kind":["Treatment"],"cancers":["Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"nuv-1511","name":"NUV-1511","tldr":"NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer.","route":"/drugs/nuv-1511/","status":"phase-2","kind":"drug","molecule":"nuv-1511","modality":"Small-molecule inhibitor","sub":"NUV-1511","facets":{"kind":["Treatment"],"cancers":["Prostate cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"obi-902","name":"OBI-902","tldr":"OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/obi-902/","status":"phase-2","kind":"drug","molecule":"obi-902","modality":"Antibody-drug conjugate","sub":"OBI-902","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"obi-992","name":"OBI-992","tldr":"OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/obi-992/","status":"phase-2","kind":"drug","molecule":"obi-992","modality":"Antibody-drug conjugate","sub":"OBI-992","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"onvansertib","name":"Onvansertib","tldr":"Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.","route":"/drugs/onvansertib/","status":"phase-2","kind":"drug","molecule":"onvansertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"or502","name":"OR502","tldr":"OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.","route":"/drugs/or502/","status":"phase-2","kind":"drug","molecule":"or502","modality":"Monoclonal antibody","sub":"OR502","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","Melanoma","Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"pamiparib","name":"Pamiparib","tldr":"Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.","route":"/drugs/pamiparib/","status":"phase-3","kind":"drug","molecule":"pamiparib","modality":"Oral PARP inhibitor","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"parsaclisib","name":"Parsaclisib","tldr":"Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.","route":"/drugs/parsaclisib/","status":"phase-2","kind":"drug","molecule":"parsaclisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"pbp1510","name":"PBP1510","tldr":"PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/pbp1510/","status":"phase-2","kind":"drug","molecule":"pbp1510","modality":"Monoclonal antibody","sub":"PBP1510","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"pimicotinib","name":"Pimicotinib","tldr":"Pimicotinib is an oral kinase inhibitor from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, in registered phase 2 trials for tenosynovial giant cell tumour.","route":"/drugs/pimicotinib/","status":"phase-2","kind":"drug","molecule":"pimicotinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Tenosynovial giant cell tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"ponsegromab","name":"Ponsegromab","tldr":"Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/ponsegromab/","status":"phase-3","kind":"drug","molecule":"ponsegromab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"prtx007","name":"PRTX007","tldr":"PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.","route":"/drugs/prtx007/","status":"phase-2","kind":"drug","molecule":"prtx007","modality":"Small-molecule inhibitor","sub":"PRTX007","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"radotinib","name":"Radotinib","tldr":"Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.","route":"/drugs/radotinib/","status":"phase-3","kind":"drug","molecule":"radotinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"regn7075","name":"REGN7075","tldr":"REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/regn7075/","status":"phase-2","kind":"drug","molecule":"regn7075","modality":"Bispecific antibody","sub":"REGN7075","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"rem-422","name":"REM-422","tldr":"REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.","route":"/drugs/rem-422/","status":"phase-2","kind":"drug","molecule":"rem-422","modality":"Small-molecule inhibitor","sub":"REM-422","facets":{"kind":["Treatment"],"cancers":["Salivary gland cancers","Adenoid cystic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."},{"label":"Adenoid cystic carcinoma","href":"/cancers/adenoid-cystic-carcinoma/","tip":"Adenoid cystic carcinoma is a slow but relentless cancer of the salivary glands that creeps along nerves and comes back years later, often in the lungs. Surgery with radiotherapy is the only cure, chemotherapy barely works, and the tablets lenvatinib and axitinib can hold spreading disease still for months rather than shrink it."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"rnk05047","name":"RNK05047","tldr":"RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/rnk05047/","status":"phase-2","kind":"drug","molecule":"rnk05047","modality":"Targeted protein degrader","sub":"RNK05047","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"roginolisib","name":"Roginolisib","tldr":"Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/roginolisib/","status":"phase-2","kind":"drug","molecule":"roginolisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"rv001v","name":"RV001V","tldr":"RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer.","route":"/drugs/rv001v/","status":"phase-2","kind":"drug","molecule":"rv001v","modality":"Cancer vaccine","sub":"RV001V","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"rvu120","name":"RVU120","tldr":"RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.","route":"/drugs/rvu120/","status":"phase-2","kind":"drug","molecule":"rvu120","modality":"Small-molecule inhibitor","sub":"RVU120","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"sabatolimab","name":"Sabatolimab","tldr":"Sabatolimab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.","route":"/drugs/sabatolimab/","status":"phase-2","kind":"drug","molecule":"sabatolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"samuraciclib","name":"Samuraciclib","tldr":"Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.","route":"/drugs/samuraciclib/","status":"phase-2","kind":"drug","molecule":"samuraciclib","modality":"Oral CDK inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"selicrelumab","name":"Selicrelumab","tldr":"Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.","route":"/drugs/selicrelumab/","status":"phase-2","kind":"drug","molecule":"selicrelumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"shandong-new-time-pharmaceutical","name":"Shandong New Time Pharmaceutical","tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.","route":"/companies/shandong-new-time-pharmaceutical/","kind":"company","avatar":"org","sub":"Shandong, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"skb105","name":"SKB105","tldr":"SKB105 is an antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/skb105/","status":"phase-2","kind":"drug","molecule":"skb105","modality":"Antibody-drug conjugate","sub":"SKB105","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"sotevtamab","name":"Sotevtamab","tldr":"Sotevtamab is a monoclonal antibody from Alethia Biotherapeutics, in registered phase 2 trials for colorectal cancer.","route":"/drugs/sotevtamab/","status":"phase-2","kind":"drug","molecule":"sotevtamab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"spartalizumab","name":"Spartalizumab","tldr":"Spartalizumab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.","route":"/drugs/spartalizumab/","status":"phase-2","kind":"drug","molecule":"spartalizumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"stp938","name":"STP938","tldr":"STP938 is a small-molecule inhibitor from Step Pharma, SAS, in registered phase 2 trials for non-Hodgkin lymphoma.","route":"/drugs/stp938/","status":"phase-2","kind":"drug","molecule":"stp938","modality":"Small-molecule inhibitor","sub":"STP938","facets":{"kind":["Treatment"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tenalisib","name":"Tenalisib","tldr":"Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.","route":"/drugs/tenalisib/","status":"phase-2","kind":"drug","molecule":"tenalisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"theo-260","name":"THEO-260","tldr":"THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.","route":"/drugs/theo-260/","status":"phase-2","kind":"drug","molecule":"theo-260","modality":"Oncolytic virus","sub":"THEO-260","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tilt-123","name":"TILT-123","tldr":"TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.","route":"/drugs/tilt-123/","status":"phase-2","kind":"drug","molecule":"tilt-123","modality":"Oncolytic virus","sub":"TILT-123","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tj-biopharma","name":"TJ Biopharma","tldr":"TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab.","route":"/companies/tj-biopharma/","kind":"company","logo":"/logos/tj-biopharma.png","avatar":"org","sub":"Shanghai, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"tng260","name":"TNG260","tldr":"TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/tng260/","status":"phase-2","kind":"drug","molecule":"tng260","modality":"Small-molecule inhibitor","sub":"TNG260","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tno155","name":"TNO155","tldr":"TNO155 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/tno155/","status":"phase-2","kind":"drug","molecule":"tno155","modality":"Small-molecule inhibitor","sub":"TNO155","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tqb2868","name":"TQB2868","tldr":"TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/tqb2868/","status":"phase-2","kind":"drug","molecule":"tqb2868","modality":"Bispecific antibody","sub":"TQB2868","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tqb3702","name":"TQB3702","tldr":"TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.","route":"/drugs/tqb3702/","status":"phase-2","kind":"drug","molecule":"tqb3702","modality":"Small-molecule inhibitor","sub":"TQB3702","facets":{"kind":["Treatment"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tqb3909","name":"TQB3909","tldr":"TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/tqb3909/","status":"phase-2","kind":"drug","molecule":"tqb3909","modality":"Small-molecule inhibitor","sub":"TQB3909","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tst001","name":"TST001","tldr":"TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/tst001/","status":"phase-2","kind":"drug","molecule":"tst001","modality":"Monoclonal antibody","sub":"TST001","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tst003","name":"TST003","tldr":"TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.","route":"/drugs/tst003/","status":"phase-2","kind":"drug","molecule":"tst003","modality":"Monoclonal antibody","sub":"TST003","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"tuspetinib","name":"Tuspetinib","tldr":"Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.","route":"/drugs/tuspetinib/","status":"phase-2","kind":"drug","molecule":"tuspetinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"upifitamab-rilsodotin","name":"Upifitamab rilsodotin","tldr":"Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.","route":"/drugs/upifitamab-rilsodotin/","status":"phase-2","kind":"drug","molecule":"upifitamab-rilsodotin","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"utomilumab","name":"Utomilumab","tldr":"Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer.","route":"/drugs/utomilumab/","status":"phase-3","kind":"drug","molecule":"utomilumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"vactosertib","name":"Vactosertib","tldr":"Vactosertib is an oral serine/threonine kinase inhibitor from MedPacto, Inc., in registered phase 2 trials for osteosarcoma.","route":"/drugs/vactosertib/","status":"phase-2","kind":"drug","molecule":"vactosertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"vb15010","name":"VB15010","tldr":"VB15010 is a small-molecule inhibitor from Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in registered phase 2 trials for ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/vb15010/","status":"phase-2","kind":"drug","molecule":"vb15010","modality":"Small-molecule inhibitor","sub":"VB15010","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Prostate cancer","Pancreatic ductal adenocarcinoma","Biliary tract cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"vibostolimab","name":"Vibostolimab","tldr":"Vibostolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/vibostolimab/","status":"phase-2","kind":"drug","molecule":"vibostolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"vistusertib","name":"Vistusertib","tldr":"Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/vistusertib/","status":"phase-2","kind":"drug","molecule":"vistusertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"vudalimab","name":"Vudalimab","tldr":"Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.","route":"/drugs/vudalimab/","status":"phase-2","kind":"drug","molecule":"vudalimab","modality":"Bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"wjb001","name":"WJB001","tldr":"WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/wjb001/","status":"phase-2","kind":"drug","molecule":"wjb001","modality":"Small-molecule inhibitor","sub":"WJB001","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"zalifrelimab","name":"Zalifrelimab","tldr":"Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/zalifrelimab/","status":"phase-2","kind":"drug","molecule":"zalifrelimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"pipeline","href":"/tagged/pipeline/","tip":"Every record tagged pipeline."}]},"sortKeys":{"year":0}},{"id":"zhuhai-yufan-biotechnologies","name":"Zhuhai Yufan Biotechnologies","tldr":"Zhuhai Yufan Biotechnologies is a Chinese developer in Zhuhai that sponsors 2 registered cancer trials of PRJ1-3024.","route":"/companies/zhuhai-yufan-biotechnologies/","kind":"company","avatar":"org","sub":"Zhuhai, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}}]